Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has granted 34,550 restricted stock units (RSUs) to two new employees. The RSUs will vest over four years, with 25% vesting annually on each grant date anniversary. The grants were issued under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment. Vesting is contingent upon continued employment with Solid Biosciences through each vesting date.

AI-generated analysis. Not financial advice.

News Market Reaction – SLDB

-1.13%

1 alert

-1.13% News Effect

On the day this news was published, SLDB declined 1.13%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (“RSUs”) to two newly hired employees.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

What type of RSUs did Solid Biosciences (SLDB) grant to new employees in June 2025?

Solid Biosciences granted 34,550 restricted stock units that vest in four equal annual installments over four years to two newly hired employees.

How does the vesting schedule work for Solid Biosciences' June 2025 RSU grants?

The RSUs vest in four equal installments, with 25% vesting on each anniversary of the grant date until the fourth anniversary.

What is the purpose of Solid Biosciences' 2024 Inducement Stock Incentive Plan?

The plan is designed to provide equity incentives as material inducement for new employees to join the company, in compliance with Nasdaq Listing Rule 5635(c)(4).

What happens to the RSUs if an employee leaves Solid Biosciences?

The RSUs only vest if the employee maintains continued service with the company through each applicable vesting date.